These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 19646924)

  • 1. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
    Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
    Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.
    Tabrizi SJ; Scahill RI; Durr A; Roos RA; Leavitt BR; Jones R; Landwehrmeyer GB; Fox NC; Johnson H; Hicks SL; Kennard C; Craufurd D; Frost C; Langbehn DR; Reilmann R; Stout JC;
    Lancet Neurol; 2011 Jan; 10(1):31-42. PubMed ID: 21130037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.
    Tabrizi SJ; Scahill RI; Owen G; Durr A; Leavitt BR; Roos RA; Borowsky B; Landwehrmeyer B; Frost C; Johnson H; Craufurd D; Reilmann R; Stout JC; Langbehn DR;
    Lancet Neurol; 2013 Jul; 12(7):637-49. PubMed ID: 23664844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.
    Chen L; Hua J; Ross CA; Cai S; van Zijl PCM; Li X
    J Neurosci Res; 2019 Apr; 97(4):467-479. PubMed ID: 30489648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis.
    Scahill RI; Zeun P; Osborne-Crowley K; Johnson EB; Gregory S; Parker C; Lowe J; Nair A; O'Callaghan C; Langley C; Papoutsi M; McColgan P; Estevez-Fraga C; Fayer K; Wellington H; Rodrigues FB; Byrne LM; Heselgrave A; Hyare H; Sampaio C; Zetterberg H; Zhang H; Wild EJ; Rees G; Robbins TW; Sahakian BJ; Langbehn D; Tabrizi SJ
    Lancet Neurol; 2020 Jun; 19(6):502-512. PubMed ID: 32470422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington's disease.
    Wu D; Faria AV; Younes L; Mori S; Brown T; Johnson H; Paulsen JS; Ross CA; Miller MI;
    Hum Brain Mapp; 2017 Oct; 38(10):5035-5050. PubMed ID: 28657159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resting-state connectivity stratifies premanifest Huntington's disease by longitudinal cognitive decline rate.
    Polosecki P; Castro E; Rish I; Pustina D; Warner JH; Wood A; Sampaio C; Cecchi GA
    Sci Rep; 2020 Jan; 10(1):1252. PubMed ID: 31988371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.
    Scahill RI; Hobbs NZ; Say MJ; Bechtel N; Henley SM; Hyare H; Langbehn DR; Jones R; Leavitt BR; Roos RA; Durr A; Johnson H; Lehéricy S; Craufurd D; Kennard C; Hicks SL; Stout JC; Reilmann R; Tabrizi SJ;
    Hum Brain Mapp; 2013 Mar; 34(3):519-29. PubMed ID: 22102212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline multimodal information predicts future motor impairment in premanifest Huntington's disease.
    Castro E; Polosecki P; Rish I; Pustina D; Warner JH; Wood A; Sampaio C; Cecchi GA
    Neuroimage Clin; 2018; 19():443-453. PubMed ID: 29984153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
    Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
    Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetization transfer imaging in 'premanifest' Huntington's disease.
    Jurgens CK; Bos R; Luyendijk J; Witjes-Ané MN; van der Grond J; Middelkoop HA; Roos RA
    J Neurol; 2010 Mar; 257(3):426-32. PubMed ID: 19823894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.
    Hart EP; Dumas EM; Giltay EJ; Middelkoop HA; Roos RA
    J Huntingtons Dis; 2013; 2(2):137-47. PubMed ID: 25063511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapping linked to function and structure in premanifest and symptomatic Huntington disease.
    Bechtel N; Scahill RI; Rosas HD; Acharya T; van den Bogaard SJ; Jauffret C; Say MJ; Sturrock A; Johnson H; Onorato CE; Salat DH; Durr A; Leavitt BR; Roos RA; Landwehrmeyer GB; Langbehn DR; Stout JC; Tabrizi SJ; Reilmann R
    Neurology; 2010 Dec; 75(24):2150-60. PubMed ID: 21068430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study.
    Hobbs NZ; Henley SM; Ridgway GR; Wild EJ; Barker RA; Scahill RI; Barnes J; Fox NC; Tabrizi SJ
    J Neurol Neurosurg Psychiatry; 2010 Jul; 81(7):756-63. PubMed ID: 19955112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease.
    Henley SM; Wild EJ; Hobbs NZ; Scahill RI; Ridgway GR; Macmanus DG; Barker RA; Fox NC; Tabrizi SJ
    J Neurol; 2009 Feb; 256(2):203-12. PubMed ID: 19266143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.
    Moss DJH; Pardiñas AF; Langbehn D; Lo K; Leavitt BR; Roos R; Durr A; Mead S; ; ; Holmans P; Jones L; Tabrizi SJ
    Lancet Neurol; 2017 Sep; 16(9):701-711. PubMed ID: 28642124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early grey matter changes in structural covariance networks in Huntington's disease.
    Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
    Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease.
    Minkova L; Gregory S; Scahill RI; Abdulkadir A; Kaller CP; Peter J; Long JD; Stout JC; Reilmann R; Roos RA; Durr A; Leavitt BR; Tabrizi SJ; Klöppel S;
    Neuroimage Clin; 2018; 17():312-324. PubMed ID: 29527479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease.
    Vinther-Jensen T; Larsen IU; Hjermind LE; Budtz-Jørgensen E; Nielsen TT; Nørremølle A; Nielsen JE; Vogel A
    Orphanet J Rare Dis; 2014 Jul; 9():114. PubMed ID: 25026978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.